APO Research
Talk to an analyst

APO RESEARCH · REPORT

Proliferative Vitreoretinopathy (PVR) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025179 pages

Choose your research edition.

Industry ResearchProliferative Vitreoretinopathy (PVR) Therapeutics Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Growth and Trends Forecast to 203275 pages · $3,450 USDMarket StructureGlobal Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Proliferative Vitreoretinopathy (PVR) Therapeutics Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Proliferative Vitreoretinopathy (PVR) Therapeutics Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Proliferative Vitreoretinopathy (PVR) Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Proliferative Vitreoretinopathy (PVR) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Proliferative Vitreoretinopathy (PVR) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Proliferative Vitreoretinopathy (PVR) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Proliferative Vitreoretinopathy (PVR) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Proliferative Vitreoretinopathy (PVR) Therapeutics include Novartis AG, RXi Pharmaceuticals Corp and Promedior Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Proliferative Vitreoretinopathy (PVR) Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Proliferative Vitreoretinopathy (PVR) Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Proliferative Vitreoretinopathy (PVR) Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Proliferative Vitreoretinopathy (PVR) Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Company

Novartis AG

RXi Pharmaceuticals Corp

Promedior Inc

Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Type

PRM-167

XOMA-089

Others

Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Application

Clinic

Hospital

ASCs

Others

Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Proliferative Vitreoretinopathy (PVR) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Proliferative Vitreoretinopathy (PVR) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Proliferative Vitreoretinopathy (PVR) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Proliferative Vitreoretinopathy (PVR) Therapeutics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Proliferative Vitreoretinopathy (PVR) Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Proliferative Vitreoretinopathy (PVR) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Proliferative Vitreoretinopathy (PVR) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Trends Table 2. Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Drivers Table 3. Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Opportunities and Challenges Table 4. Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Restraints Table 5. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Manufacturers Table 9. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers, Product Type & Application Table 13. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Proliferative Vitreoretinopathy (PVR) Therapeutics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of PRM-167 Table 17. Major Manufacturers of XOMA-089 Table 18. Major Manufacturers of Others Table 19. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2021-2026) & (k units) Table 21. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2027-2032) & (k units) Table 22. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type (2021-2026) Table 23. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type (2027-2032) Table 24. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2021-2026) & (k units) Table 26. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2027-2032) & (k units) Table 27. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Type (2021-2026) Table 28. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Clinic Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of ASCs Table 32. Major Manufacturers of Others Table 33. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2021-2026) & (k units) Table 35. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2027-2032) & (k units) Table 36. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2021-2026) Table 37. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2027-2032) Table 38. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2021-2026) & (k units) Table 40. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2027-2032) & (k units) Table 41. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Application (2021-2026) Table 42. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Application (2027-2032) Table 43. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2021-2026) & (k units) Table 45. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Region (2021-2026) Table 46. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecasted by Region (2027-2032) & (k units) Table 47. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021-2026) & (k units) Table 50. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2027-2032) & (k units) Table 51. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021-2026) & (k units) Table 53. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2027-2032) & (k units) Table 54. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021-2026) & (k units) Table 56. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2027-2032) & (k units) Table 57. South America, Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. South America, Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021-2026) & (k units) Table 59. South America, Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2027-2032) & (k units) Table 60. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Region (2021-2026) Table 64. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Region (2027-2032) Table 65. Novartis AG Company Information Table 66. Novartis AG Business Overview Table 67. Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio Table 69. Novartis AG Recent Development Table 70. RXi Pharmaceuticals Corp Company Information Table 71. RXi Pharmaceuticals Corp Business Overview Table 72. RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio Table 74. RXi Pharmaceuticals Corp Recent Development Table 75. Promedior Inc Company Information Table 76. Promedior Inc Business Overview Table 77. Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio Table 79. Promedior Inc Recent Development Table 80. Key Raw Materials Table 81. Raw Materials Key Suppliers Table 82. Proliferative Vitreoretinopathy (PVR) Therapeutics Distributors List Table 83. Proliferative Vitreoretinopathy (PVR) Therapeutics Customers List Table 84. Research Programs/Design for This Report Table 85. Authors List of This Report Table 86. Secondary Sources Table 87. Primary Sources List of Figures Figure 1. Proliferative Vitreoretinopathy (PVR) Therapeutics Product Image Figure 2. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (2021-2032) & (k units) Figure 5. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Proliferative Vitreoretinopathy (PVR) Therapeutics Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. PRM-167 Image Figure 9. XOMA-089 Image Figure 10. Others Image Figure 11. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type (2021-2032) Figure 14. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Type (2021-2032) Figure 17. Clinic Image Figure 18. Hospital Image Figure 19. ASCs Image Figure 20. Others Image Figure 21. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2021-2032) Figure 24. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Application (2021-2032) Figure 27. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 28. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Country (2021-2032) Figure 29. U.S. Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 30. Canada Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 31. Mexico Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Country (2021-2032) Figure 34. Germany Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 35. France Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 36. U.K. Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 37. Italy Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 38. Netherlands Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Country (2021-2032) Figure 41. China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 42. Japan Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 43. South Korea Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 44. Southeast Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 45. India Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 46. Australia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Country (2021-2032) Figure 49. Brazil Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 50. South Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 51. Saudi Arabia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 52. Turkey Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 53. Argentina Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 54. UAE Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 55. Egypt Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 56. Chile Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 57. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Figure 60. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Figure 62. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Proliferative Vitreoretinopathy (PVR) Therapeutics Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Proliferative Vitreoretinopathy (PVR) Therapeutics Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • PRM-167
  • XOMA-089
  • Others
Applications
  • Clinic
  • Hospital
  • ASCs
  • Others
Companies covered
  • Novartis AG
  • RXi Pharmaceuticals Corp
  • Promedior Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Dynamics
  1. 2.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Trends
  2. 2.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Drivers
  3. 2.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Restraints
3 Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Manufacturers
  1. 3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Manufacturers (2021-2026)
  3. 3.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers, Product Type & Application
  7. 3.7 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Proliferative Vitreoretinopathy (PVR) Therapeutics Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Proliferative Vitreoretinopathy (PVR) Therapeutics Tier 1, Tier 2, and Tier 3
4 Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Type
  1. 4.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Type Introduction
  2. 4.1.1 PRM-167
  3. 4.1.2 XOMA-089
  4. 4.1.3 Others
  5. 4.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type
  6. 4.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2021-2032)
  8. 4.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type (2021-2032)
  9. 4.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type
  10. 4.3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2021-2032)
  12. 4.3.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Type (2021-2032)
5 Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Application
  1. 5.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 ASCs
  5. 5.1.4 Others
  6. 5.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application
  7. 5.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2021-2032)
  9. 5.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2021-2032)
  10. 5.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application
  11. 5.3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2021-2032)
  13. 5.3.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Application (2021-2032)
6 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region
  1. 6.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2021-2032)
  3. 6.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2021-2026)
  4. 6.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region
  1. 7.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region
  2. 7.1.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region (2021-2026)
  4. 7.1.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region (2027-2032)
  5. 7.1.4 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032)
  8. 7.2.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032)
  11. 7.3.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 RXi Pharmaceuticals Corp
  8. 8.2.1 RXi Pharmaceuticals Corp Company Information
  9. 8.2.2 RXi Pharmaceuticals Corp Business Overview
  10. 8.2.3 RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio
  12. 8.2.5 RXi Pharmaceuticals Corp Recent Developments
  13. 8.3 Promedior Inc
  14. 8.3.1 Promedior Inc Company Information
  15. 8.3.2 Promedior Inc Business Overview
  16. 8.3.3 Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio
  18. 8.3.5 Promedior Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Value Chain Analysis
  2. 9.1.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Proliferative Vitreoretinopathy (PVR) Therapeutics Production Mode & Process
  6. 9.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Distributors
  9. 9.2.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst